Biomea Total Other Income Expense Net from 2010 to 2026
| BMEA Stock | USD 1.50 0.03 2.04% |
Total Other Income Expense Net | First Reported 2020-06-30 | Previous Quarter 536 K | Current Value 4.4 M | Quarterly Volatility 1.2 M |
Macro event markers
Review Biomea Fusion financial statements over time to add context on performance and capital structure. It connects Net Interest Income of 6.8 M, Interest Income of 6.8 M or Depreciation And Amortization of 2.1 M and ratios such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.57 with Biomea Fusion Valuation and Volatility context.
Biomea | Total Other Income Expense Net | Build AI portfolio with Biomea Stock |
Analyzing Biomea Fusion's Total Other Income Expense Net over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Other Income Expense Net has evolved provides context for assessing Biomea Fusion's current valuation and future prospects.
Latest Biomea Fusion's Total Other Income Expense Net Growth Pattern
Below is the plot of the Total Other Income Expense Net of Biomea Fusion over the last few years. It is Biomea Fusion's Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biomea Fusion's overall financial position and show how it may be relating to other accounts over time.
| Total Other Income Expense Net | 10 Years Trend |
|
Total Other Income Expense Net |
| Timeline |
Biomea Total Other Income Expense Net Regression Statistics
| Arithmetic Mean | 1,747,572 | |
| Geometric Mean | 33,162 | |
| Coefficient Of Variation | 175.58 | |
| Mean Deviation | 2,458,573 | |
| Median | -3,000 | |
| Standard Deviation | 3,068,353 | |
| Sample Variance | 9.4T | |
| Range | 8.9M | |
| R-Value | 0.75 | |
| Mean Square Error | 4.4T | |
| R-Squared | 0.56 | |
| Significance | 0.0005 | |
| Slope | 455,525 | |
| Total Sum of Squares | 150.6T |
Biomea Total Other Income Expense Net History
About Biomea Fusion Inc
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. The company was incorporated in 2017 and is headquartered in Redwood City, California. Biomea Fusion operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. The profile for Biomea Fusion integrates fundamentals, price behavior, and sector exposure. Cycle exposure remains aligned with broader market trends. Biomea Fusion has a market cap of 103.93 M, ROE of -2.09%. 
Rifka Kats ยท Member of Macroaxis Editorial Board
Methodology
Unless otherwise specified, financial data for Biomea Fusion is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Biomea (USA Stocks:BMEA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We use public filings and market reference sources with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO) as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Biomea Fusion may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Biomea Stock is Curated By:
Rifka Kats ยท Member of Macroaxis Editorial BoardAlso Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Biomea Stock Analysis
A structured review of Biomea Fusion often starts with core financial statements and trend context. Ratios and trend metrics help frame Biomea Fusion's operating context. Key reports that frame Biomea Fusion Stock are listed below:Review Biomea Fusion Correlation against competitors for Biomea Fusion. This provides competitive positioning context. To learn how to invest in Biomea Stock, please use our How to Invest in Biomea Fusion guide.Analysis related to Biomea Fusion should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
The market value of Biomea Fusion is measured differently than book value, which reflects Biomea accounting equity. Biomea Fusion's market capitalization is 103.93 M. With a P/B ratio of 6.61, the market values Biomea Fusion well above its book equity. Enterprise value stands at 63.46 M. Intrinsic value is an analytical estimate of Biomea Fusion's underlying worth that can differ from price and book value. Valuation methods help interpret those gaps.
Note that Biomea Fusion's intrinsic value and market price are different measures derived from different inputs. For Biomea Fusion, key inputs include a P/B ratio of 6.61, and ROE of -2.09%. Market price reflects the current exchange level formed by active bids and offers.